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Abstract Hypoﬁbrinolysis is a key abnormality in diabetes but the role of impaired clot lysis in
predicting vascular events and mortality in this population is yet to be determined. We
aimed to investigate the relationship between ﬁbrin clot properties and clinical
outcomes in patients with diabetes and recent acute coronary syndrome (ACS). Plasma
samples were collected at hospital discharge from 974 ACS patients with diabetes
randomised to clopidogrel or ticagrelor in the PLATO trial. A validated turbidimetric
assay was employed to study ﬁbrin clot lysis and maximum turbidity. One-year rates of
cardiovascular (CV) death, spontaneous myocardial infarction (MI) and PLATO-deﬁned
major bleeding events were assessed after sample collection. Hazard ratios (HRs) were
determined using Cox proportional analysis. After adjusting for CV risk factors, each
50% increase in lysis time was associated with increased risk of CV death/MI (HR 1.21;
95% conﬁdence interval [CI] 1.02–1.44; p¼ 0.026) and CV death alone (HR 1.38;
1.08–1.76; p¼ 0.01). Similarly, each 50% increase in maximum turbidity was associat-
ed with increased risk of CV death/MI (HR 1.25; 1.02–1.53; p¼ 0.031) and CV death
alone (HR 1.49; 1.08–2.04; p¼ 0.014). The relationship between lysis time and the
combined outcome of CV death and MI remained signiﬁcant after adjusting for
multiple prognostic vascular biomarkers (p¼ 0.034). Neither lysis time nor maximum
turbidity was associated with major bleeding events. Impaired ﬁbrin clot lysis predicts
1-year CV death and MI in diabetes patients following ACS.
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Introduction
Upto30%ofpatientspresentingwithacute coronary syndrome
(ACS) suffer from diabetes mellitus.1,2 These individuals have
worse vascular outcomes despite contemporary therapies.1,3,4
A ‘pro-thrombotic’ state, characterised by adverse ﬁbrin clot
properties and increased platelet reactivity, has been repeat-
edly described in patientswith diabetes.5–7Despite the altered
thrombotic milieu in this condition, long-term preventative
anti-thrombotic treatmentpost-ACSremains similar compared
with individuals without diabetes.8,9 Offering more intensive
therapies may be one approach to improve outcomes, but this
can be challenging in diabetes given the heterogeneity of this
condition, which is characterised by variable risks of thrombo-
sis and bleeding.10
Potent P2Y12 inhibitors (ticagrelor/prasugrel) post-ACS
improved outcomes in patients with diabetes without an
apparent penalty of increased major bleeding compared with
clopidogrel.4,11 Targeting the protein arm of coagulation with
low-dose anti-factor Xa therapy, in addition to clopidogrel-
based dual anti-platelet therapy, was shown to reduce cardio-
vascular (CV)eventsandmortality inACSpatients, regardlessof
diabetes status.12 However, the observed increase in bleeding
and the guideline-recommended use of dual anti-platelet
therapy with ticagrelor or prasugrel, rather than clopidogrel,
has limited widespread adoption of this approach.
Clinical characteristics, such as the extentofcoronaryartery
disease, history of recurrent events or renal impairment, and
elevated CV biomarkers could help guide intensity of treat-
ment,13 but functional biomarkers that address thrombosis
risk are lacking. Identiﬁcation of such biomarkers could poten-
tially make it possible to implement tailored anti-thrombotic
therapy in this population, helping to maximise beneﬁts and
minimise risks.
Cross-sectional studieshave repeatedlyshownarelationship
betweencoronaryarterydiseaseanddenseﬁbrinnetworks that
are resistant to lysis.14–16 These associations were documented
in individuals with and without diabetes, although the latter
group was generally found to have a more thrombotic clot
phenotype.17–19Wehave recently demonstrated that impaired
ﬁbrin clot lysis independently predicts CV death following
ACS,20 indicating that theﬁbrin network has clinical prognostic
signiﬁcance. Diabetes was also associated with impaired ﬁbrin
clot lysis but the magnitude of the association between pro-
longed ﬁbrin clot lysis and adverse outcomes in diabetes
patients was not assessed.20 In this sub-analysis, we aimed to
assess the association between ﬁbrin network properties and
adverse clinical outcome in ACS patients with diabetes.
Methods
Study Population and Patient Samples
The PLATelet inhibition and patient Outcomes (PLATO) trial
was an international multi-centre, double-blind, randomised
controlled trial of ticagrelor compared with clopidogrel in
18,624 moderate-to-high-risk ACS patients.21,22 Study design
and results have been previously reported.21,22 Brieﬂy,
patients admitted with ACS were recruited within 24 hours
of symptom onset and randomised to either clopidogrel or
ticagrelor. Patients were followed up at 1 to 3, 6 to 9 and
12 months. The PLATO ﬁbrin sub-study included 4,354
patients who donated blood at hospital discharge.20 This is a
sub-group analysis involving all 974 patients with diabetes.
Citrated plasma was derived and stored at –80°C at Uppsala
Clinical Research Centre (Uppsala, Sweden) prior to transfer to
the University of Shefﬁeld (Shefﬁeld, United Kingdom) for
ﬁbrin clot analysis.
Fibrin Clot Assessment
This was performed using a turbidimetric assay as previously
described.20 Brieﬂy, plasma mixed with tissue plasminogen
activator (tPA) (83 ng/mL) was re-calciﬁed (CaCl2 7.5mM) and
clotting was initiated with thrombin (0.03 U/mL). Fibrin clot
maximum turbidity (ameasure of ﬁbrin clot density) and lysis
timeweredeterminedusingaMultiskanFC (Thermoscientiﬁc)
plate reader in all 974 plasma samples taken at hospital
discharge and 820 plasma samples taken at 1 month. All
laboratory analysis was performed blinded to clinical out-
comes, treatment allocation and other biomarker levels.
Statistical Methods
Biomarker levelswere natural log transformed before analysis.
Continuous data are presented as medians and interquartile
ranges and compared using Kruskal–Wallis tests, Wilcoxon
tests ormultivariable linear regressionmodels, as appropriate.
Categoricaldataarepresentedasnumbersandpercentagesand
compared using chi-square tests. The primary outcome of
interest was the composite of CV death and spontaneous
myocardial infarction (MI). SecondaryoutcomeswereCVdeath
alone, MI alone, PLATO-deﬁned major bleeding and all-cause
mortality. Cox-proportional hazards models were used to
estimate hazard ratios (HRs) and 95% conﬁdence intervals
(CIs). HRs are expressed per 50% ﬁbrin variable level increase.
We adjusted for clinical risk factors (model 1) and for known
prognostic biomarkers. Model 1 included all clinical risk fac-
tors, including randomised treatment, age, gender, body mass
index (BMI), smoking history, hypertension, dyslipidaemia,
chronic kidney disease (CKD), ST-elevation ACS and previous
MI, congestiveheart failure, revascularisation, ischaemic stroke
or peripheral artery disease. Prognostic biomarkers were
added sequentially to adjustment model 1. Model 2 included
adjustment formodel 1,white cell count andC-reactive protein
(CRP). Model 3 included adjustment for model 1 clinical risk
except for CKD, white cell count, CRP and cystatin C. Model 4
included adjustment for model 3 risk factors, troponin T and
N-terminal pro B-typenatriuretic peptide (NT-proBNP).Model
5 included all model 4 risk factors and growth differentiation
factor-15. Restricted cubic splines were used to visually assess
the relationship between ﬁbrin clot properties and clinical
outcomes. Interactions between prognostic value of ﬁbrin clot
parameters and each of randomised treatment, treatment
strategy and treatment with low-molecular-weight heparin
(LMWH) (within 2 days of sampling) were assessed using
restricted cubic splines. Mean standard deviation ﬁbrin
clot properties at hospital discharge and 1 month were com-
pared using Wilcoxon signed-rank test. p-Values< 0.05 from
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two-tailed tests were considered statistically signiﬁcant.
p-Values were not adjusted for multiple testing. All statistical
analyses were performed at Uppsala Clinical Research Centre
using R statistics software (Version 3.3.2; R Foundation for
Statistical Computing, Vienna, Austria).
Results
Diabetes, Associated Conditions and Biomarkers
►Table 1 outlines the difference between patients with and
without diabetes. Diabetes showed associations with CV risk
factors, including increased age, increased BMI, hypertension,
hyperlipidaemia, CKDandperipheral artery disease. However,
smoking was less prevalent in diabetes patients. Higher pro-
portions presented with non-ST-elevation ACS, were females
and had previous MI, stroke, congestive heart failure or
revascularisation compared with patients without diabetes.
After adjustment for risk factors and clinical characteristics
(model 1), ﬁbrin clot lysis time and maximum turbidity were
signiﬁcantly higher in patients with diabetes compared with
those without. The majority of other prognostic and inﬂam-
matory biomarkers were signiﬁcantly higher in patients with
diabetes (►Table 2).
Fibrin Clot Properties, Clinical Characteristics and
Biomarker Levels
The correlation between ﬁbrin clot maximum turbidity and
lysis time was weak (r¼ 0.37, p< 0.001).
►Tables 3 and 4 summarise clinical characteristics and
biomarker levels across the four quartile groups of ﬁbrin clot
properties. BMI and the proportion of females increasedwith
increasing quartile groups of lysis time. Similarly, the preva-
lence of CKD was highest in the highest lysis time quartile
group. Levels of prognostic and inﬂammatory biomarkers
signiﬁcantly increased with increasing quartile groups of
both lysis time and maximum turbidity.
Platelet count and low-density lipoprotein (LDL) choles-
terol levels increasedwith increasingﬁbrin clot lysis timebut
showed no relationship tomaximum turbidity. There was no
signiﬁcant difference in the proportion of patients receiving
ticagrelor across the four lysis time quartile groups.
The correlation between lysis time and the inﬂammatory
biomarker CRP was weak (r¼ 0.29, p< 0.001). In contrast,
the relationship between ﬁbrin clot maximum turbidity and
CRP appeared more linear (r¼ 0.63, p< 0.001). Both lysis
time (r¼ 0.09, p¼ 0.005) and maximum turbidity (r¼ 0.41,
p< 0.001) were signiﬁcantly, thoughweakly, correlatedwith
troponin T.
Glycated haemoglobin (HbA1c) also signiﬁcantly increased
with increasing lysis time (►Table 2) but no association with
maximum turbidity was found (►Table 4). Insulin treatment
did not show associations with ﬁbrin clot properties.
Table 1 Clinical characteristics in diabetes and non-diabetes
patients
Variable Diabetes
n¼ 974
No diabetes
n¼ 3,380
p-Value
Demographics and risk factors
Age (y) 64 (56–72) 61 (53–70) < 0.001
Females 342 (35.1%) 931 (27.5%) < 0.001
Body mass
index (kg/m2)
29 (26–33) 27 (25–30) < 0.001
Current smoker 232 (23.8%) 1363 (40.3%) < 0.001
Hypertension 806 (82.8%) 2059 (60.9%) < 0.001
Hyperlipidaemia 533(54.7%) 1307(38.7%) < 0.001
Previous MI 261 (26.8%) 585 (17.3%) < 0.001
Congestive
heart failure
86 (8.8%) 163 (4.8%) < 0.001
Previous PCI 153 (15.7%) 375 (11.1%) < 0.001
Previous CABG 78 (8.0%) 143 (4.2%) < 0.001
Previous stroke 48 (4.9%) 103 (3.0%) 0.005
Peripheral
artery disease
82 (8.4%) 191 (5.7%) 0.002
CKD 62 (6.4%) 85 (2.5%) < 0.001
Randomised treatment
Ticagrelor 490 (50.3%) 1687 (49.9%) 0.83
Presentation
STE-ACS 354 (36.3%) 1668 (49.3%) < 0.001
Abbreviations: CABG, coronary artery bypass graft; CKD, chronic kidney
disease; MI, myocardial infarction; PCI, percutaneous coronary inter-
vention; STE-ACS, ST-elevation acute coronary syndrome.
Note: Values are medians (interquartile ranges [IQRs]) for continuous
data and n (%) for categorical data. p-Values were calculated using
Wilcox test for age and chi - square test for categorical variable.
Table 2 Biomarker levels in diabetes and non-diabetes patients
Biomarker Diabetes
n¼ 974
No diabetes
n¼ 3,380
Adjusted
p-value
Lysis time (s) 732
(594–1,002)
684
(558–864)
< 0.001
Maximum
turbidity (AU)
0.51
(0.39–0.64)
0.49
(0.38–0.62)
0.004
Troponin
T (ng/L)
521
(105–1,535.5)
716
(123.5–2,264)
0.2
NT-proBNP
(pmol/L)
621.5
(247–1,578)
562.5
(236–1,253)
< 0.001
Cystatin C
(mg/L)
1.0 (0.8–1.2) 0.9 (0.8–1.1) 0.14
GDF-15 1,931
(1422–2,935)
1,469
(1,121–2,062)
< 0.001
CRP (mg/L) 15 (5.9–35) 14 (5.3–32) < 0.001
IL-6 5.8 (3.3–11) 5.5 (2.9–10) 0.003
WCC 9.2 (7.6–11.5) 9.4 (7.4–11.7) < 0.001
HbA1c 7.5 (6.6–8.9) 5.9 (5.6–6.2) < 0.001
Abbreviations: AU, arbitrary unit; CRP, C-reactive protein; GDF-15,
growth differentiation factor 15; HbA1C, glycated haemoglobin; IL,
interleukin; NT-proBNP, N-terminal pro B-type natriuretic peptide; WCC,
white cell count.
Note: p-Values were calculated using multivariable linear regression
analysis with adjustment to all clinical characteristics (model 1). All
biomarkers were measured at hospital discharge except for WCC and
HbA1c which were measured at baseline.
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Fibrin Clot Properties and Clinical Outcomes
During follow-up, 48 patients (4.9%) had CV death, 72 (7.4%)
had MI, 67 (2.9%) had major bleeding and 21 (2.2%) had non-
coronary artery bypass graft-related major bleeding.
The probability of the combined outcome of CV death and
MIwas higher with increasing values of lysis time (►Fig. 1A).
This was driven primarily by increased risk of CV death with
increasing lysis time (►Fig. 1B). There was no clear relation-
ship between lysis time and major bleeding events.
Similarly, the probability of the combined outcome of CV
death and MI was higher with increasing maximum turbidity
(►Fig. 2A). The highest quartile group, in particular, appeared
Table 3 Clinical characteristics and biomarkers across quartile groups of lysis time in patients with diabetes
Variables Lysis time (s) quartile group p-Value
Q1 (< 594)
n¼ 251
Q2 (594–732)
n¼ 239
Q3 (732–1,002)
n¼ 243
Q4 (> 1,002)
n¼ 241
Demographics and medical history
Age (y) 65 (58–72) 65 (57–72) 64 (56–72) 64 (55–71) 0.25
Female 67 (26.7%) 73 (30.5%) 84 (34.6%) 118 (49.0%) < 0.001
BMI (kg/m2) 27.8
(25.5–31.8)
28.7
(26.4–32.5)
29.4
(26.4–32.4)
29.8
(26.3–33.9)
0.004
Hypertension 188 (74.9%) 208 (87.0%) 206 (84.8%) 204 (84.6%) 0.002
Previous MI 68 (27.1%) 61 (25.5%) 71 (29.2%) 61 (25.3%) 0.75
Previous stroke 7 (2.8%) 13 (5.4%) 13 (5.3%) 15 (6.2%) 0.31
PAD 14 (5.6%) 23 (9.6%) 23 (9.5%) 22 (9.1%) 0.31
CKD 8 (3.2%) 15 (6.3%) 15 (6.2%) 24 (10.0%) 0.02
Treatment strategy
Invasive 159 (63.3%) 146 (61.1%) 164 (67.5%) 157 (65.1%) 0.51
Inpatient PCI 152 (60.6%) 140 (58.6%) 154 (63.4%) 146 (60.6%) 0.76
Inpatient CABG 8 (3.2%) 6 (2.5%) 10 (4.1%) 12 (5%) 0.5
Ticagrelor 118 (47%) 114 (47.7%) 130 (53.5%) 128 (53.1%) 0.32
Supine systolic BPa 140 (120–150) 140 (120–150) 140 (120–150) 140 (121–152) 0.64
Biomarkers
Troponin T (ng/L) 326
(86–1,186)
371
(73–1,415)
604
(139–1,602)
703
(149–1,868)
0.01
NT-proBNP (pmol/L) 486
(238–1,052)
602
(222–1,358)
760
(307–2,118)
716
(279–2,197)
0.001
Cystatin C (mg/L) 0.92
(0.77–1.15)
0.94
(0.76–1.16)
0.94
(0.76–1.26)
1.04
(0.86–1.38)
< 0.001
GDF-15 (ng/L) 1,842
(1,435–2,651)
1,864
(1,414–2,741)
1,933
(1,392–2,891)
2,139
(1,479–3,689)
0.01
CRP (mg/L) 9 (4–21) 14 (5–27) 17 (8–52) 24 (11–58) < 0.001
WCC ( 109/L) 8.5 (7.1–10.6) 9.4 (7.8–11.3) 9.3 (8.0–11.8) 9.9 (7.8–12.1) < 0.001
Platelets ( 109/L) 218 (191–254) 235 (197–274) 235 (194–284) 251 (203–304) < 0.001
HbA1c (%) 7.3 (6.5–8.6) 7.4 (6.4–9) 7.5 (6.6–9) 7.8 (6.8–9.1) 0.02
Glucose (mmol/L) 9.3 (7.2–12.4) 9.7 (7.3–13.8) 9.3 (7.5–13) 10.4 (7.8–13.2) 0.13
LDL (mmol/L) 2.7 (2.1–3.4) 2.8 (2.2–3.5) 3.0 (2.2–4.0) 3.0 (2.4–4.0) 0.008
HDL (mmol/L) 1.2 (1.0–1.4) 1.1 (0.9–1.4) 1.2 (1.0–1.4) 1.2 (1.0–1.3) 0.31
Pre-admission insulin treatment 56 (22.3%) 54 (22.6%) 55 (22.6%) 60 (24.9%) 0.9
Insulin treatment during admission 122 (48.6%) 115 (48.1%) 124 (51%) 139 (57.7%) 0.14
Abbreviations: BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CRP, C-reactive protein;
GDF-15, growth differentiation factor-15; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MI, myocardial
infarction; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; WCC,
white cell count.
Note: Values are medians (interquartile ranges [IQRs]) for continuous data and n (%) for categorical data. p-Values calculated using chialculat test for
categorical variables and Kruskal–Wallis test for continuous variables. Biomarkers measures at hospital discharge except for WCC, platelets, HbA1c,
glucose and cholesterol levels which were measured at baseline.
aBlood pressure measured at baseline.
Thrombosis and Haemostasis Vol. 120 No. 3/2020
Fibrinolysis and Outcomes in Diabetes ACS Patients Sumaya et al. 415
to be associated with greatest risk of CV death (►Fig. 2B). In
contrast, the probability ofmajor bleeding seemed to increase
with decreasing maximum turbidity.
After adjustment for clinical characteristics and CV
disease risk factors (model 1), each 50% increase in lysis
time was associated with increased risk of CV death/MI
(HR 1.21; 95% CI 1.02–1.44) and CV death alone (HR 1.38;
95% CI 1.08–1.76). Similarly, every 50% increase in lysis time
was associated with increased risk of all-cause mortality
after adjustment for clinical risk factors in model 1 (HR
1.47; 95% CI 1.16–1.85) and this remained signiﬁcant after
adjustment for inﬂammatory biomarkers (►Fig. 3). After
adjustment for prognostic biomarkers as well as clinical
risk factors (model 5), the relationship between lysis time
and the combined outcome of CV death and MI remained
signiﬁcant (p¼ 0.034).
Table 4 Clinical characteristics and biomarkers across quartile groups of maximum turbidity in patients with diabetes
Variables Maximum turbidity (AU) quartile group p-Value
Q1 (< 0.39)
n¼ 244
Q2 (0.39–0.51)
n¼ 243
Q3 (0.51–0.64)
n¼ 244
Q4 (> 0.64)
n¼ 243
Demographics and medical history
Age (y) 64 (56–72) 65 (57–72) 63 (56–71) 64 (57–71) 0.66
Female 88 (36.1%) 95 (39.1%) 86 (35.2%) 73 (30.0%) 0.21
BMI (kg/m2) 28.4
(25.6–32.7)
29.1
(26.3–32.7)
29.1
(26.3–33.2)
29.1
(26.0–32.3)
0.71
Hypertension 203 (83.2%) 207 (85.2%) 195 (79.9%) 201 (82.7%) 0.49
Previous MI 74 (30.3%) 76 (31.3%) 62 (25.4%) 49 (20.2%) 0.02
Previous stroke 8 (3.3%) 14 (5.8%) 12 (4.9%) 14 (5.8%) 0.54
PAD 20 (8.2%) 24 (9.9%) 14 (5.7%) 24 (9.9%) 0.30
CKD 12 (4.9%) 14 (5.8%) 15 (6.1%) 21 (8.6%) 0.37
Treatment strategy
Invasive 120 (49.2%) 156 (64.2%) 161 (66%) 189 (78%) < 0.001
Inpatient PCI 114 (46.7%) 152 (62.6%) 153 (62.7%) 173 (71.2%) < 0.001
Inpatient CABG 6 (2.5%) 4 (1.6%) 8 (3.3%) 18 (7.4%) 0.004
Ticagrelor 119 (48.8%) 106 (43.6%) 137 (56.1%) 128 (52.7%) 0.04
Supine systolic BP 140 (120–150) 140 (123–150) 140 (120–153) 140 (125–150) 0.95
Biomarkers
Troponin T (ng/L) 148
(37–579)
337
(74–1,133)
645
(193–1,708)
1,223
(525–2,781)
< 0.001
NT-proBNP (pmol/L) 345
(171–797)
535
(217–1,130)
590
(299–1,565)
1,409
(552–2,934)
< 0.001
Cystatin C (mg/L) 0.93
(0.77–1.15)
0.96
(0.78–1.21)
0.94
(0.77–1.19)
1.0
(0.83–1.37)
0.02
GDF-15 (ng/L) 1,765
(1,323–2,527)
1,926
(1,441–2,766)
1,917
(1,412–2,892)
2,268
(1,576–3,759)
<,0.001
CRP (mg/L) 5 (3–13) 10 (5–18) 18 (10–32) 50 (26–100) < 0.001
WBC ( 109/L) 8.1 (6.9–9.9) 8.8 (7.4–11.1) 9.4 (7.8–11.1) 10.7 (9–13.5) < 0.001
Platelets ( 109/L) 228 (201–263) 227 (192–273) 233 (198–276) 240 (194–285) 0.12
HbA1c (%) 7.3 (6.4–8.7) 7.6 (6.7–9.4) 7.6 (6.6–9) 7.5 (6.7–8.7) 0.27
Glucose (mmol/L) 9.0 (6.7–12.1) 9.5 (7.3–12.4) 9.7 (7.4–13) 10.5 (8–13.8) 0.004
LDL (mmol/L) 2.9 (2.1–3.5) 2.8 (2.2–3.6) 2.9 (2.3–3.9) 3.0 (2.3–3.7) 0.38
HDL (mmol/L) 1.1 (1–1.4) 1.2 (1–1.4) 1.2 (1–1.4) 1.2 (1–1.4) 0.41
Pre-admission insulin treatment 53 (21.7%) 57 (23.5%) 60 (24.6%) 55 (22.6%) 0.9
Insulin treatment during admission 114 (46.7%) 119 (49%) 129 (52.9%) 138 (56.8%) 0.12
Abbreviations: AU, arbitrary unit; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft; CKD, chronic kidney disease; CRP,
C-reactive protein; GDF-15, growth differentiation factor-15; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; LDL, low-density
lipoprotein; NT-proBNP, N-terminal pro B-type natriuretic peptide; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous
coronary intervention; WCC, white cell count.
Note: Values aremedians (interquartile ranges [IQRs]) for continuous data and n (%) for categorical data. p-Values calculated using calculated test for
categorical variables and Kruskal–Wallis test for continuous variables.
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Similarly, each 50% increase in maximum turbidity was
associated with increased risk of CV death/MI (HR 1.25; 95%
CI 1.02–1.53) and CV death alone (HR 1.49; 95% CI
1.08–2.04). These relationships lost signiﬁcance after adjust-
ment for prognostic biomarkers. There was a numerical
increase in bleeding in the lowest quartile group of maxi-
mum turbidity but this failed to reach statistical signiﬁcance
(p¼ 0.15).
The prognostic value of ﬁbrin clot lysis time was consis-
tent regardless of randomised treatment, presentation,
administration of LMWHwithin 2 days or invasive treatment
(all interaction p> 0.1) (►Fig. 4).
Similarly, the prognostic value of ﬁbrin clot lysis timewas
consistent regardless of diabetes status but the magnitude of
relationship appears to be higher in patients with diabetes
(►Fig. 5).
Fibrin Clot Properties over Time
Fibrin clot lysis time remained prolonged at 1 month
(864 406 seconds) compared with hospital discharge
Fig. 1 Relationship between ﬁbrin clot lysis time and 1-year clinical outcomes in patients with diabetes mellitus, 1-year rates of cardiovascular
(CV) death and spontaneous myocardial infarction (MI) (A) and CV death alone (B) in relation to lysis time transformed using restricted cubic
splines. Shaded areas represent 95% conﬁdence intervals. Vertical lines indicate quartiles.
Fig. 2 Relationship between ﬁbrin clot maximum turbidity and 1-year clinical outcomes in patients with diabetes mellitus, 1-year rates of
cardiovascular (CV) death and spontaneous myocardial infarction (MI) (A) and CV death alone (B) in relation to maximum turbidity (AU, arbitrary
units) transformed using restricted cubic splines. Shaded areas represent 95% conﬁdence intervals. Vertical lines indicate quartiles.
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Fig. 3 Forest plot for the associations between ﬁbrin clot lysis time and clinical outcomes following acute coronary syndrome (ACS) in patients
with diabetes. Squares represent hazard ratio (HR) estimates. Horizontal lines represent 95% conﬁdence intervals. Number of patients, 971 for
model 1 and 853 for subsequent models. Model 1: Clinical characteristics including randomised treatment, age, gender, body mass index (BMI),
smoking history, hypertension, dyslipidaemia, chronic kidney disease (CKD), ST-elevation ACS and previous MI, congestive heart failure,
revascularisation, ischaemic stroke or peripheral artery disease; Model 2: Clinical characteristics as per model 1 þ C-reactive protein
(CRP)þwhite cell count (WCC); Model 3: All characteristics and biomarkers as per model 2 (except CKD)þ cystatin C; Model 4: All characteristics
and biomarkers as per model 3 þ troponin þN-terminal pro B-type natriuretic peptide (NT-proBNP); Model 5: All characteristics and biomarkers
as per model 4þ growth differentiation factor 15 (GDF-15).
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(863 445 seconds) (p¼ 0.64) despite a drop in overall
maximum turbidity (0.44 0.14 vs. 0.53 0.2; p< 0.001).
Discussion
For the ﬁrst time, in a large cohort of ACS patients with
diabetes, wehave shownprolonged ﬁbrin clot lysis to predict
CV death and MI after adjustment for clinical risk predictors
as well as traditional and novel prognostic biomarkers. We
have also shown ﬁbrin clot lysis time to remain prolonged at
1month following ACS, despite a drop in ﬁbrin clot turbidity.
Being a functional assay, ourmethodology takes into account
quantitative and qualitative changes in various clotting
factors, thus giving an overall assessment of ﬁbrin-related
thrombosis risk. The independent association between
impaired lysis and worse ischaemic outcomes may indicate
that some patients may beneﬁt from further optimisation of
anti-thrombotic therapy, for example, by dropping dual anti-
platelet therapy and replacing it with a combination of a
single anti-platelet agent and an anticoagulant, since antico-
agulant therapy potentiates ﬁbrinolysis.23–25 However, the
safety and efﬁcacy of such an approach requires further
research.
Despite the large number of patients included in our
study, the study lacks sufﬁcient power to detect an indepen-
dent relationship between individual components of the
primary endpoint and ﬁbrin clot properties. However, the
trend of associationwith both CV death andMI is consistent.
Fig. 4 Relationship between ﬁbrin clot lysis time and cardiovascular death according to randomised treatment (A), low-molecular-weight
heparin treatment (B), presentation (C) and treatment strategy (D). One-year rates of cardiovascular death in relation to lysis time, transformed
using restricted cubic splines. Shaded areas represent 95% conﬁdence intervals, vertical lines indicate quartiles. LMWH, low-molecular-weight
heparin; NSTE-ACS, non-ST-elevation acute coronary syndrome; STEMI, ST-elevation myocardial infarction.
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Diabetes and prolonged lysis are both associated with
many high-risk patient characteristics and prognostic bio-
markers. We have adjusted for many potential confounders
and although the association between prolonged ﬁbrin clot
lysis and CV death/spontaneous MI remained signiﬁcant,
including many confounders in adjustment models is a
limitation. Reassuringly, the results are very similar with
the many different models we tested for.
Another limitation of our methodology is that we studied
ﬁbrinolysis in plasma samples rather than whole blood. This
may exclude the cellular effects on the ﬁbrinolytic pathway.
However, our results provide a ‘proof-of-concept’ of the
importance of intrinsic ﬁbrinolysis in predicting outcomes.
Theveryweakcorrelationbetweenﬁbrinclot lysispotential
and troponin levels indicates a possible pathophysiological
linkwithworse outcomes that is independentof the size ofMI.
Fibrin clot maximum turbidity had a stronger relationship
with CRP as well as troponin and NT-proBNP. This is to be
expected as turbidity reﬂects ﬁbrin clot density, which is
more closely related to ﬁbrinogen levels, and ﬁbrinogen levels
arewell known to increasewith inﬂammation, such asmay be
provoked by large MIs.20
Although ﬁbrin clot turbidity is only marginally higher in
the diabetes population compared with individuals without
diabetes, lysis time is signiﬁcantly longer in the former group,
consistent with previous studies.7,26 There are several diabe-
tes-speciﬁc mechanisms that lead to impaired clot lysis,
including glycation of ﬁbrinogen, which results in more com-
pact clots that resist ﬁbrinolysis,27 increased incorporation of
anti-ﬁbrinolytic proteins into the clot28 and glycation of
plasminogen, which inhibits plasmin generation and modu-
lates enzyme activity, thus further impairing the ﬁbrinolytic
process.29 These previous ﬁndings may explain our results
demonstrating a relationship between HbA1c and clot lysis
time. Improving glycaemic control can modulate outcomes
post-ACS and a reduction inﬁbrin clot lysis timemay be one of
the mechanisms involved.30 Similarly, approaches to amelio-
rate inﬂammationmay be successful at improving lysis poten-
tial. In studies involving human aortic endothelial cells, CRP
resulted in increased plasminogen activator inhibitor-1 ex-
pression and reduction in tPA activity, which may explain the
observed relationship between increased inﬂammation and
pro-thrombotic changes in ﬁbrin parameters.31,32 Although
diabetes was associated with increased maximum turbidity,
there was no clear association between this ﬁbrin parameter
and glycaemic control. This suggests that the relationship
between glycaemic control and lysis time is related to alter-
ation in the ﬁbrinolytic proteins rather than changes in ﬁbrin
clot structure in the cohort studied. However, it should be
noted that over-treatment of high glucose levels and precipi-
tation of hypoglycaemia can also impair ﬁbrin clot lysis,33
potentially explaining the inconsistent relationship between
improved glycaemic control and outcome observed in clinical
studies.34–36
LDL cholesterol levels and platelet count increased with
increasing lysis time. These observations are intriguing
and support previously reported effects of cholesterol and
increased platelet reactivity on ﬁbrinolysis.37 However, ran-
domisation to ticagrelor was not associated with ﬁbrinolysis
potential and this suggests that platelet reactivity has limited
impact on ﬁbrin clot lysis in plasma. Statins and fenoﬁbrates
were previously shown to improve ﬁbrinolysis.38 We are
unable to conﬁrm this in our study as> 90% of patients
were receiving statins but the relationship between increased
lysis and increased LDL levels suggests a role for cholesterol-
lowering therapy in modulating ﬁbrinolysis.
Increased incorporation of anti-ﬁbrinolytic proteins into
the ﬁbrin clot represents another mechanism for impaired
Fig. 5 Relationship between ﬁbrin clot lysis time and clinical outcomes according to diabetes status. One-year rates of cardiovascular (CV) death
or spontaneous myocardial infarction (MI) (A) and CV death alone (B) in relation to lysis time, transformed using restricted cubic splines,
according to diabetes status.
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ﬁbrinolysis in diabetes.39 Developing therapies against one
or more of these proteins may represent a targeted approach
that helps to improve prognosis in ACS patients with diabe-
tes, while minimising bleeding risk.
The relationship between impaired ﬁbrin clot lysis and
female gender is consistent with previously observed results
in other cohorts of high-risk vascular patients with type 2
diabetes.26,40 However, another study, in a younger cohort,
found no difference in lysis potential between males and
females.41 The latter study was much smaller than the other
two, including a limited number of younger subjects who
had type 1 rather than type 2 diabetes, and these differences
in study populations are likely to explain the discrepancies.
Prolonged lysis may be one mechanism for the reduction in
CV protection in women with diabetes and further work is
needed in this area to understand the exact pathways
involved.
Conclusion
Adverse ﬁbrin clots that resist lysis predict CV death and
MI in ACS patients with diabetes despite contemporary
therapies. The relationship between high-risk vascular
conditions and impaired lysis provide potential mechanistic
insights into recurrent events. The weak correlation
between ﬁbrin clot lysis potential and troponin indicates
that the association with worse outcomes is relatively
independent of the magnitude of MI. Developing strategies
to improve lysis tendency may help improve prognosis in
high-risk ACS patients and future research in this area is
warranted.
What is known about this topic?
• Diabetes is associated with worse outcomes following
ACS.
• The relationship between ﬁbrin clot properties and
clinical outcomes in diabetes patients presenting with
ACS remains unknown.
What does this paper add?
• Prolonged ﬁbrin clot lysis predicts cardiovascular
death and spontaneous myocardial infarction in dia-
betes patients presenting with ACS.
• Further research is needed to establish the suitability
of targeting reduced ﬁbrinolysis to aid improve out-
comes in diabetes patients with ACS.
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